New York Times Articles on Cancer Immunotherapy and Cancer Treatment Options
Curators: Aviva Lev-Ari, PhD, RN, Stephen J Williams, PhD and Tilda Barliya, PhD
The following articles,
Here are some ways cancer can thwart the new immunotherapy drugs
Laurie McGinley July 13, 2016
The list of cancers that can be treated by immunotherapy keeps growing
By Laurie McGinley April 19
were brought to my attention by Tilda Barliya, PhD, on our R&D Team, DrugDiscovery @LPBI Group, it stimulated the following curation in several Parts:
This article has three parts:
- Part One: LPBI Group: A Key Opinion Leader (KOL) in Cancer and Genomics
- Part Two: History of Cancer Immunotherapy
- Part Three: New York Times Articles on Cancer Immunotherapy and Cancer Treatment Options
LPBI Group: A Key Opinion Leader (KOL) in Cancer and Genomics
Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com
Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com
Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN
Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015
Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015
Genomics Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Cancer Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
History of Cancer Immunotherapy
Pioneers of Cancer Cell Therapy: Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors
Curator: Aviva Lev-Ari, PhD, RN
In 1987, researchers identified cytotoxic T-lymphocyte antigen 4, or CTLA-4. Allison found that CTLA-4 prevents T cells from attacking tumor cells. He wondered whether blocking CTLA-4 would allow the immune system to make those attacks. In 1996, Allison showed that antibodies against CTLA-4 allowed the immune system to destroy tumors in mice. In 1999, biotech firm Medarex acquired rights to the antibody. In 2010, Medarex acquirer Bristol-Myers Squibb reported that patients with metastatic melanoma lived an average of 10 months on the antibody, versus 6 months without it. It was the first time any treatment had extended life in advanced melanoma in a randomized trial.
In the early 1990s, a biologist discovered a molecule expressed in dying T cells, which he called programmed death 1, or PD-1 and which he recognized as another disabler of T cells. An antibody that targeted PD-1 was developed and by 2008 produced remission in multiple subjects across multiple cancer types. In 2013, clinicians reported that across 300 patients tumors shrunk by about half or more in 31% of those with melanoma, 29% with kidney cancer and 17% with lung cancer.
In 1997 rituximab, the first antibody treatment for cancer, was approved by the FDA for treatment of follicular lymphoma. Since this approval, 11 other antibodies have been approved for cancer; alemtuzumab (2001), ofatumumab (2009) and ipilimumab (2011).
In 2003 cytokines such as interleukin were administered. The adverse effects of intravenously administered cytokines led to the extraction, in vitro expansion against a tumour antigen and reinjection of the cells with appropriate stimulatory cytokines.
However, with both anti–CTLA-4 and anti–PD-1, some tumors continued to grow before vanishing months later. Some patients kept responding after the antibody had been discontinued. Some patients, developed side effects including inflammation of the colon or of the pituitary gland.
After success harvesting T cells from tumors, expanding them in the lab and reinfusing them into patients reduced tumors, in 2010, Steven Rosenberg announced chimeric antigen receptor therapy, or CAR therapy. This technique is a personalized treatment that involves genetically modifying each patient’s T cells to target tumor cells. It produced complete remission in a majority of leukemia patients, although some later relapsed.
New York Times Articles on Cancer Immunotherapy and Cancer Treatment Options
Some of the most promising advances in cancer research in recent years involve treatments known as immunotherapy. These advances are spurring billions of dollars in investment by drug companies, and are leading to hundreds ofJuly 31, 2016 – – Health – Print Headline: “A Guide to Immunotherapy, an Evolving but Promising Field”
declared him in remission. It was a result that put him at the vanguard of a new generation of cancer treatment called immunotherapy that casts into sharp relief the harshness of how we have long treated cancer and the less gruelingAugust 01, 2016 – – Health – Print Headline: “As Death Lurked, Tumors Melted”
The New York Times would like to hear from doctors and patients who have experience giving or receiving immunotherapy treatment for cancer.July 31, 2016 – – Health – Print Headline: “Have You Received Immunotherapy Treatment for Cancer?”
The hot new field of immunotherapy got a shock on Friday when a best-selling new drug failed as an initial treatment for lung cancer in a clinical trial. Bristol-Myers Squibb said Friday that the drug, Opdivo, had not slowed theAugust 06, 2016 – – Business Day – Print Headline: “Immunotherapy Drug Fails Lung Cancer Trial”
The Food and Drug Administration on Wednesday approved a newimmunotherapy drug from Roche to treat bladder cancer, a form of cancer for which there have been no significant new medicines in years. The drug, called Tecentriq, is theMay 19, 2016 – – Business Day – Print Headline: “F.D.A. Approves Immunotherapy Drug for Treatment of Bladder Cancer”
media as the early president of Facebook. Now he wants to pioneer in a field that is already jumping with activity: cancer immunotherapy. Mr. Parker is announcing Wednesday that he is donating $250 million to a new effort that willApril 13, 2016 – – Business Day – Print Headline: “Facebook and Napster Pioneer to Push Innovation in Cancer Treatment”
Sloan Kettering Cancer Center in New York, recommended an experimental treatment: immunotherapy. Rather than attacking the cancer directly, as chemo does, immunotherapy tries to rally the patient’s own immuneJuly 31, 2016 – – Health – Print Headline: “A Sickened Body as Cancer Weapon”
She also took part in a clinical trial at Johns Hopkins for Opdivo, an immunotherapy drug made by the pharmaceutical company Bristol-Myers Squibb. Briefly stated, immunotherapy is a recently developed, highlyAugust 09, 2016 – – Opinion – Print Headline: “Drug Ads vs. Drug Reality”
Sean Parker discusses his support of immunotherapy research.April 13, 2016 – – Business Day – Print Headline: “Sean Parker on Cancer Research”
family and many friends. Contributions in his memory may be made to Memorial Sloan Kettering Cancer Center, Melanoma and Immunotherapy Research under Dr. Jedd Wolchok. 1/3July 17, 2016 – – Paid Death Notices – Print Headline: “Paid Notice: Deaths SPRAYREGEN, NICHOLAS (NICK)”
St. and Amsterdam Ave. Contributions in his memory may be made to Memorial Sloan Kettering Cancer Center, Melanoma and Immunotherapy Research under Dr. Jedd Wolchok. 1/3July 14, 2016 – – Paid Death Notices – Print Headline: “Paid Notice: Deaths SPRAYREGEN, NICHOLAS (NICK)”
Sloan Kettering Cancer Center. This radical, science-fictionlike therapy differs sharply from the more established type of immunotherapy, developed by other researchers. Those off-the-shelf drugs, known as checkpoint inhibitors,August 02, 2016 – – Health – Print Headline: “Setting Body’s ‘Serial Killers’ Loose on Cancer”